Baxter International Inc. Stock Forecast 2025-2029: Is This Undervalued Medtech Giant Ready to Soar?

Baxter International Inc. is undergoing a transformative journey in 2025, with its stock price poised for potential growth amid strategic restructuring and a robust medtech portfolio. Could this undervalued gem be your next big investment? Dive into our stock price forecast and uncover the opportunities awaiting savvy investors.

Operations

Baxter International Inc., headquartered in Deerfield, Illinois, is a global leader in the medical technology sector, delivering a wide range of healthcare products and solutions. Founded in 1931, the company focuses on transformative innovation to address chronic and acute medical conditions, serving hospitals, clinics, dialysis centers, and patients at home under physician supervision. Baxter operates across three primary business segments as of 2023: Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals, with its Kidney Care segment in the process of being separated into a standalone entity.

• The Medical Products and Therapies segment includes sterile intravenous (IV) solutions, infusion systems, parenteral nutrition therapies, and advanced surgical products like hemostats and sealants.
• The Healthcare Systems and Technologies segment, bolstered by the 2021 acquisition of Hillrom, offers connected care solutions such as smart bed systems, patient monitoring tools, and surgical equipment.
• The Pharmaceuticals segment provides specialty injectable drugs, inhaled anesthetics, and drug compounding services.

Baxter’s products are distributed globally through a direct sales force, independent distributors, and specialty pharmacies, with operations spanning the Americas, Europe, the Middle East, Africa, and Asia-Pacific. In 2023, the company advanced its strategic restructuring, including the sale of its BioPharma Solutions business and plans to spin off its Kidney Care unit, aiming to streamline its focus and enhance operational efficiency.

Financial Performance and Ratios

Baxter’s financial performance in 2023 reflected resilience amid strategic shifts. According to its full-year results released in February 2024, sales from continuing operations reached $14.81 billion, up 2% on a reported basis and 3% at constant currency, driven by demand for essential healthcare products.

However, U.S. GAAP diluted earnings per share (EPS) from continuing operations showed a loss of ($0.15), impacted by special items such as separation costs and restructuring charges. On an adjusted basis, diluted EPS was $2.60, showcasing underlying profitability despite challenges like inflation and supply chain pressures.

Key financial ratios provide deeper insight.

• Baxter’s gross margin on an adjusted basis typically hovers around 40-43%, reflecting its ability to manage production costs in its medtech portfolio.
• The operating margin, adjusted for special items, was approximately 12-14% in 2023, bolstered by operational efficiency initiatives under a new operating model.
• The debt-to-equity ratio remains elevated post-Hillrom acquisition, estimated at around 1.5-2.0, as the company balances debt repayment with investments in growth.
• Baxter generated $532 million in free cash flow (operating cash flow less capital expenditures) in 2022, a figure likely improved in 2023 as it executed divestitures, though exact 2023 cash flow figures post-date some available data.

These metrics underscore Baxter’s focus on stabilizing its financial position while navigating a transformative period.

Baxter International Inc Stock Price Performance

Baxter’s (NYSE: BAX) stock price performance has been a mixed story in recent years, reflecting both market dynamics and company-specific developments. As of early 2025, BAX shares traded around $30-$36, down from a 52-week high of approximately $44.66 and above a low of $28.34, according to market data trends.

The stock experienced a significant decline from its 2022 highs, driven by rising interest rates, goodwill impairments (notably a $3.1 billion charge in 2022), and uncertainty surrounding the Kidney Care spinoff. However, a strong Q4 2023 earnings report—featuring $3.89 billion in sales (up 4% reported) and adjusted EPS of $0.88—sparked renewed investor interest, with an 8.5% stock price jump post-earnings in February 2024.

Analyst sentiment remains cautious but optimistic, with a consensus “Hold” rating based on a blend of buy, hold, and sell recommendations. Posts on X in early 2025 noted bullish outlooks tied to product unveilings like Voalte Linq at HIMSS, though options activity suggested some trader skepticism.

Competitive Landscape

Baxter International Inc. is a prominent player in the healthcare industry, known for its innovative medical technologies and lifesaving products. The company operates in more than 100 countries and has a diversified portfolio that includes products in renal care, medication delivery, pharmaceuticals, and biotechnology.

Key Competitors

Baxter faces intense competition from several major companies in the healthcare and medical device industry, including:

• Medtronic
• Fresenius Medical Care
• B. Braun
• Johnson & Johnson
• GE Healthcare

Competitive Advantages

Baxter’s competitive advantages include:

• A diverse product portfolio
• Strong global presence
• Robust research and development (R&D) capabilities

Industry Trends and Challenges

• Baxter is impacted by several industry trends and challenges, such as:
• Increasing demand for healthcare products and services
• Advancements in technology
• Regulatory changes
• Pricing pressures
• Intense competition

Opportunities for Growth

Future opportunities for Baxter include:

• Expanding into emerging markets
• Developing innovative products
• Forming strategic partnerships

Baxter’s strategic outlook involves focusing on innovation, operational efficiency, and customer satisfaction to maintain a competitive edge.

Investment Insight

While the recent decline in net operating cash flow and free cash flow (FCF) raises some concerns, the company’s high net profitability ratios reveal a determined stance in an extremely competitive arena. The broader set of operating performance metrics also suggests that the stock is considerably undervalued, which in turn presents investors with an enticing purchasing opportunity. Coupled with the company’s durable competitive edge and robust long-term growth outlook, this undervaluation could well be a signal to consider buying shares.

Baxter International Inc Stock Forecast**

2025–2029 Price Targets: 

Year	MIN Target	MAX Target
2025	36.80	57.13
2026	38.59	59.91
2027	40.46	62.82
2028	42.43	65.88
2029	44.50	69.97

When to buy and Investment Tips

Amid a pronounced bear market, the stock has secured support at the $28.34 level. The significant bounce it has experienced from this point suggests that now is a prime moment to buy, especially when considering the favorable PEG ratio and equity risk premium metrics.

Dividend Policy and Buyback Policy

Baxter has historically prioritized returning value to shareholders, though its capital allocation strategy has shifted amid recent transformations. The company pays a quarterly dividend of $0.29 per share, translating to an annual yield of around 3.0-3.2% at current stock prices—a competitive figure in the medtech space.

In 2022, Baxter returned approximately $600 million to shareholders through dividends and share repurchases, though buybacks have since tapered as the company focuses on deleveraging post-Hillrom and funding its Kidney Care separation.

Conclusion

Baxter International’s stock presents a compelling case in 2025—undervalued yet resilient, with a promising growth trajectory through 2029. While challenges like debt and competition linger, its innovation-driven strategy and shareholder-friendly dividends signal a potential breakout. Is it time to buy? The numbers suggest yes.

A cup of coffee from you for this excellent analysis.

Or Donate:

Company’s Site.

More US Stocks.

*Investment analysis involves scrutinizing over 50 different criteria to assess a company's ability to generate shareholder value. This comprehensive approach includes tracking revenue, profit, equity dynamics, dividend payments, cash flow, debt and financial management, stock price trends, bankruptcy risk, F-Score, and more. These metrics are consolidated into a straightforward Investment Scoreboard, which effectively helps predict future stock price movements.
**Use the price forecast to manage the risk of your investments.